Literature DB >> 33135055

Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2.

Asif Shajahan1, Stephanie Archer-Hartmann1, Nitin T Supekar1, Anne S Gleinich1, Christian Heiss1, Parastoo Azadi1.   

Abstract

The emergence of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created the need for development of new therapeutic strategies. Understanding the mode of viral attachment, entry and replication has become a key aspect of such interventions. The coronavirus surface features a trimeric spike (S) protein that is essential for viral attachment, entry and membrane fusion. The S protein of SARS-CoV-2 binds to human angiotensin converting enzyme 2 (hACE2) for entry. Herein, we describe glycomic and glycoproteomic analysis of hACE2 expressed in HEK293 cells. We observed high glycan occupancy (73.2 to 100%) at all seven possible N-glycosylation sites and surprisingly detected one novel O-glycosylation site. To deduce the detailed structure of glycan epitopes on hACE2 that may be involved in viral binding, we have characterized the terminal sialic acid linkages, the presence of bisecting GlcNAc and the pattern of N-glycan fucosylation. We have conducted extensive manual interpretation of each glycopeptide and glycan spectrum, in addition to using bioinformatics tools to validate the hACE2 glycosylation. Our elucidation of the site-specific glycosylation and its terminal orientations on the hACE2 receptor, along with the modeling of hACE2 glycosylation sites can aid in understanding the intriguing virus-receptor interactions and assist in the development of novel therapeutics to prevent viral entry. The relevance of studying the role of ACE2 is further increased due to some recent reports about the varying ACE2 dependent complications with regard to age, sex, race and pre-existing conditions of COVID-19 patients.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ACE2 glycosylation; ACE2 site mapping; COVID-19 receptor; SARS-CoV-2 receptor; hACE2 N-glycosylation

Mesh:

Substances:

Year:  2021        PMID: 33135055      PMCID: PMC7665489          DOI: 10.1093/glycob/cwaa101

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  42 in total

1.  Inhibition of Protein N-Glycosylation Blocks SARS-CoV-2 Infection.

Authors:  Aitor Casas-Sanchez; Alessandra Romero-Ramirez; Eleanor Hargreaves; Cameron C Ellis; Brian I Grajeda; Igor L Estevao; Edward I Patterson; Grant L Hughes; Igor C Almeida; Tobias Zech; Álvaro Acosta-Serrano
Journal:  mBio       Date:  2022-02-15       Impact factor: 7.867

2.  Serum N-glycomic profiling may provide potential signatures for surveillance of COVID-19.

Authors:  Yongjing Xie; Michael Butler
Journal:  Glycobiology       Date:  2022-09-19       Impact factor: 5.954

3.  Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte.

Authors:  Nunzia D'Onofrio; Lucia Scisciola; Celestino Sardu; Maria Consiglia Trotta; Marisa De Feo; Ciro Maiello; Pasquale Mascolo; Francesco De Micco; Fabrizio Turriziani; Emilia Municinò; Pasquale Monetti; Antonio Lombardi; Maria Gaetana Napolitano; Federica Zito Marino; Andrea Ronchi; Vincenzo Grimaldi; Anca Hermenean; Maria Rosaria Rizzo; Michelangela Barbieri; Renato Franco; Carlo Pietro Campobasso; Claudio Napoli; Maurizio Municinò; Giuseppe Paolisso; Maria Luisa Balestrieri; Raffaele Marfella
Journal:  Cardiovasc Diabetol       Date:  2021-05-07       Impact factor: 9.951

Review 4.  SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models.

Authors:  G Kanimozhi; B Pradhapsingh; Charan Singh Pawar; Haseeb A Khan; Salman H Alrokayan; N Rajendra Prasad
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

5.  SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.

Authors:  Tyler N Starr; Nadine Czudnochowski; Zhuoming Liu; Fabrizia Zatta; Young-Jun Park; Amin Addetia; Dora Pinto; Martina Beltramello; Patrick Hernandez; Allison J Greaney; Roberta Marzi; William G Glass; Ivy Zhang; Adam S Dingens; John E Bowen; M Alejandra Tortorici; Alexandra C Walls; Jason A Wojcechowskyj; Anna De Marco; Laura E Rosen; Jiayi Zhou; Martin Montiel-Ruiz; Hannah Kaiser; Josh R Dillen; Heather Tucker; Jessica Bassi; Chiara Silacci-Fregni; Michael P Housley; Julia di Iulio; Gloria Lombardo; Maria Agostini; Nicole Sprugasci; Katja Culap; Stefano Jaconi; Marcel Meury; Exequiel Dellota; Rana Abdelnabi; Shi-Yan Caroline Foo; Elisabetta Cameroni; Spencer Stumpf; Tristan I Croll; Jay C Nix; Colin Havenar-Daughton; Luca Piccoli; Fabio Benigni; Johan Neyts; Amalio Telenti; Florian A Lempp; Matteo S Pizzuto; John D Chodera; Christy M Hebner; Herbert W Virgin; Sean P J Whelan; David Veesler; Davide Corti; Jesse D Bloom; Gyorgy Snell
Journal:  Nature       Date:  2021-07-14       Impact factor: 69.504

6.  Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.

Authors:  Emma C Thomson; Laura E Rosen; James G Shepherd; Roberto Spreafico; Ana da Silva Filipe; Jason A Wojcechowskyj; Chris Davis; Luca Piccoli; David J Pascall; Josh Dillen; Spyros Lytras; Nadine Czudnochowski; Rajiv Shah; Marcel Meury; Natasha Jesudason; Anna De Marco; Kathy Li; Jessica Bassi; Aine O'Toole; Dora Pinto; Rachel M Colquhoun; Katja Culap; Ben Jackson; Fabrizia Zatta; Andrew Rambaut; Stefano Jaconi; Vattipally B Sreenu; Jay Nix; Ivy Zhang; Ruth F Jarrett; William G Glass; Martina Beltramello; Kyriaki Nomikou; Matteo Pizzuto; Lily Tong; Elisabetta Cameroni; Tristan I Croll; Natasha Johnson; Julia Di Iulio; Arthur Wickenhagen; Alessandro Ceschi; Aoife M Harbison; Daniel Mair; Paolo Ferrari; Katherine Smollett; Federica Sallusto; Stephen Carmichael; Christian Garzoni; Jenna Nichols; Massimo Galli; Joseph Hughes; Agostino Riva; Antonia Ho; Marco Schiuma; Malcolm G Semple; Peter J M Openshaw; Elisa Fadda; J Kenneth Baillie; John D Chodera; Suzannah J Rihn; Samantha J Lycett; Herbert W Virgin; Amalio Telenti; Davide Corti; David L Robertson; Gyorgy Snell
Journal:  Cell       Date:  2021-01-28       Impact factor: 66.850

7.  Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2.

Authors:  Kien Nguyen; Srirupa Chakraborty; Rachael A Mansbach; Bette Korber; Sandrasegaram Gnanakaran
Journal:  Viruses       Date:  2021-05-17       Impact factor: 5.818

Review 8.  Glycosylation of SARS-CoV-2: structural and functional insights.

Authors:  Asif Shajahan; Lauren E Pepi; Daniel S Rouhani; Christian Heiss; Parastoo Azadi
Journal:  Anal Bioanal Chem       Date:  2021-07-07       Impact factor: 4.478

9.  Structures of synthetic nanobody-SARS-CoV-2-RBD complexes reveal distinct sites of interaction and recognition of variants.

Authors:  David Margulies; Javeed Ahmad; Jiansheng Jiang; Lisa Boyd; Allison Zeher; Rick Huang; Di Xia; Kannan Natarajan
Journal:  Res Sq       Date:  2021-06-16

Review 10.  In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses.

Authors:  Saeid Najafi Fard; Linda Petrone; Elisa Petruccioli; Tonino Alonzi; Giulia Matusali; Francesca Colavita; Concetta Castilletti; Maria Rosaria Capobianchi; Delia Goletti
Journal:  Biomed Res Int       Date:  2021-06-21       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.